We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Ixico Plc | IXI | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 11.50 | 08:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 11.50 | 11.50 | 11.50 | 11.50 | 11.50 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 25/5/2024 11:05 by 40 fathoms Contract delays in the CNS space are very much a fact and not IXI specific, you can see this in the outlook statements of their peers.IXI have really backed themselves in to corner with their reckless spending on just about everything over the past 5 years. insane salaries, undisciplined R&D spending, overstaffing, a useless board. This is now coming back to plague them. Even if they win significant numbers of large contracts in the next 6 months they do not have sufficient working capital to be certain they can execute. This will also impact sponsors confidence to contract with them. They need an additional 2-3 million cash to correct this situation. In truth the best outcome for existing shareholders is for the board to conduct a process and sell the business. Of course they won't do that, they will tap the market for cash equivalent to 60% to 80% of the current market cap. Almost doubling the share count in the process. On the plus side they have many on the register that can stand their round, on the negative side any CR does not necessarily, permanently, fix the problem. One point in the IMC prevention where I think they are being a bit disingenuous is with respect to the balance of their contract book. They have pointed to the shift from large late stage trials to smaller early stage trials. While it is true this reduces their risk to any individual trial descope or cancellation, what they have not mentioned is the huge failure rate for early stage CNS trials. Although it is improving, it has historically been about 95% for phase I CNS trials. So having early stage trials can lead to large later stage trials, the probability of any individual trial progressing to a later stage is very, very low. |
Posted at 10/5/2023 07:29 by halfpenny Now IXI have a strong platform with cash in the bank, AI products and a strong order book for 2023 and great outlook for 2024.IXI with strong AI products being released puts them ahead of the market. Investors now circulating IXI at these levels. Future looking great for IXI. |
Posted at 24/4/2023 11:45 by halfpenny IXI now likely being pursued by a couple on investors who missed out on Medica Group Plc today.Investors now circulating IXI at these levels. Only large deals with a share price above 33p can keep them away. Future looking great for IXI. |
Posted at 12/4/2023 09:13 by halfpenny Trading update very positive on Pipeline sales with great results for 2023/4.IXI with large order flow so expect RNS soon. They have a record breaking year ahead and great growth as stated recently. Future looking bright for IXI. Get ready and How High as the can move up rapidly as we get RNS flowing soon Bright Future.. |
Posted at 04/4/2023 13:04 by halfpenny I agree with more orders in the pipeline.Maybe a Takeover still on the cards as IXICO price levels are attractive at the current levels. IXI future is very bright so get ready for dramatic price increases ahead. Following yesterday RNS Expect further RNS soon on great Deals. Get ready for a rapid rise as demand increases. Also IXI are at Target takeover levels. |
Posted at 04/4/2023 07:28 by halfpenny Another Order for IXI so expect plenty more in the pipeline. Takeover target at these levels so needs rapid orders. Interesting times ahead so got more at these levels.IXI have a huge increasing interest of its AI Products , is this when the company orders and sales pipeline grows quickly. Maybe a Takeover still on the cards as IXICO price levels are attractive at the current levels. IXI future is very bright so get ready for dramatic price increases ahead. Following yesterday RNS Expect further RNS soon on great Deals. |
Posted at 13/3/2023 06:49 by halfpenny IXI have a huge increasing interest of its AI Products , is this when the company orders and sales pipeline grows quickly.Maybe a Takeover still on the cards as IXICO price levels are attractive at the current levels. IXI future is very bright so get ready for dramatic price increases ahead. Expect further RNS soon on great Deals. |
Posted at 24/2/2023 13:49 by halfpenny IXI have a huge increasing interest of its AI Products , is this when the company orders and sales pipeline grows quickly.Maybe a Takeover on the cards as IXICO price levels are attractive at the current levels. IXI future is very bright so get ready for dramatic price increases ahead. Expect RNS soon |
Posted at 19/2/2023 16:38 by halfpenny Ixico shares rise on double-digit revenue expectations for 2024 hence a record breaking year ahead and beyond..IXI can beat previous sales with a focus on Sales and New A1 Products/Services which is in high demand. The outlook and expectations are high and expect New Order demands to be high and beat market expectations. The future for IXI is bright so get ready.. |
Posted at 21/4/2022 06:33 by tomboyb IXICO plc New Contract Win21/04/2022 7:00am UK Regulatory (RNS & others) Ixico (LSE:IXI) Intraday Stock Chart Thursday 21 April 2022 Click Here for more Ixico Charts. TIDMIXI RNS Number : 8126I IXICO plc 21 April 2022 21 April 2022 IXICO plc ("IXICO" or the "Company") Contract award with a new client for a Huntington's Disease ('HD') trial worth circa GBP800,000 IXICO plc (AIM: IXI), the neuroimaging Contract Research Organisation (CRO) delivering advanced AI analytical insights in neuroscience, is pleased to announce it has been selected by a new client to support its global prospective observational study to assess participants for the early detection of HD. HD is a rare, inherited disease that causes the progressive breakdown of nerve cells in the brain affecting movement, mood and thinking abilities. The new client is a biotech company specialized in gene therapy for neurodegenerative and other genetic diseases. IXICO will provide a range of its imaging CRO and advanced analytics services across approximately 2.5 years. Having combined AI imaging biomarker analysis across many HD trials, together with centralised CRO services, IXICO is continuously enhancing its validated disease-optimised advanced analytics technology for this indication. This new contract follows our recent presentation on our new deep learning-based platform, IXIQ.Ai, at the Annual HD Therapeutics Conference in Palm Springs, a technology which IXICO will be applying to this trial. This, together with the ability to deliver its services through our proprietary TrialTracker imaging data management platform, makes IXICO the clear partner of choice for this study. Giulio Cerroni, Chief Executive Officer of IXICO, commented : " With no current cure for Huntington's, nor interventions that slow disease progression, HD is a devastating rare neurological condition with significant unmet medical needs. We are delighted to further extend our client base and support identifying new insights into this challenging rare neurodegenerative disease. We are committed to ensuring that our validated machine learning AI data analytics, combined with the quality assurance of our TrialTracker platform, enable clients to unlock new insights into disease progression and drug development." For further information please contact: |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
